Novo Nordisk Stock Falls 3.46% on June 8 Amid Lilly ADA Dominance and CagriSema Non-Inferiority Question
Novo Nordisk closed 3.46% lower Monday June 8 as investor attention focused on Lilly's clear ADA win and on CagriSema's failure to demonstrate non-inferiority against a competitor on some obesity endpoints. CVS Caremark's earlier formulary tilt toward Lilly's Zepbound (announced in late May, effective October 1) and the broader oral GLP-1 picture compound the pressure. Novo's Wegovy pill remains the only US-approved oral, but the next-wave pipeline narrative now skews to Lilly.